Back to Sites

Harare Family Care CRS

Site Number

31890

Address

Cnr Josiah Tongogara/Mazowe Street
Parirenyatwa Annex
Harare,
Zimbabwe

IMPAACT Members at this Site

David Mburuzabudu CAB Member

Audry Tasaranarwo CAB Member

Reginald Maonedzo CAB Representative

Zvenyika Alfred Gomo Co-Investigator

Francis Jaji Co-Investigator

Mavis Kahwemba Co-Investigator

Suzen Maonera Co-Investigator

Hilda Mujuru Co-Investigator

Richard Musana Co-Investigator

Mercy Mutambanengwe Co-Investigator

Rachel Mahachi CRS Coordinator

Sukunena Maturure CRS Coordinator

Mutsawashe Bwakura-Dangarembizi CRS Leader

James Hakim CRS Leader

Gift Chareka CTU Coordinator

Zvavahera Chirenje CTU Principal Investigator

Bola Adedeji DAIDS PO

Rufaro Katsande Data Manager

Tichaona Vhembo Investigator

Marshall Munjoma Laboratory Manager/Supervisor

Bangani Kusakara Medical Officer

Tapiwa Mbengeranwa Medical Officer

Tsungai Mhembere Pharmacist of Record

Studies at this Site

P1112: Monoclonal Antibody PK Study

DAIDS Number

11903

Research Area

Therapeutics

Study Status

Participants Off Study and Primary Analysis Completed

P1115: Very Early Intensive Treatment of Infants Living with HIV to Achieve HIV Remission: A Phase I/II Proof of Concept Study

DAIDS Number

11954

Research Area

Cure and Immunotherapy

Study Status

Enrolling

IMPAACT 2001: A Phase I/II Trial of the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-infected and HIV-1-uninfected Pregnant and Postpartum Women with Latent Tuberculosis Infection

DAIDS Number

12026

Research Area

Tuberculosis

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2009 : Pharmacokinetics, Feasibility, Acceptability, and Safety of Oral Pre-Exposure Prophylaxis for Primary HIV Prevention during Pregnancy and Postpartum in Adolescents and Young Women and their Infants

DAIDS Number

30020

Research Area

Therapeutics

Study Status

Closed to Follow Up

IMPAACT 2008: Phase I/II Multisite, Randomized, Controlled Study of Monoclonal Antibody VRC01 with Combination Antiretroviral Therapy to Promote Clearance of HIV-1-Infected Cells in Infants

DAIDS Number

20735

Research Area

Cure and Immunotherapy

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2010: VESTED

DAIDS Number

30129

Research Area

Therapeutics

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2016: Evaluating a Group-Based Intervention to Improve Mental Health and ART Adherence Among Youth Living with HIV in Low Resource Settings

DAIDS Number

38506

Research Area

Brain and Mental Health

Study Status

Closed to Accrual

IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

DAIDS Number

38609

Research Area

Therapeutics

Study Status

Enrolling

IMPAACT 2024 : Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age with and without HIV

DAIDS Number

38747

Research Area

Tuberculosis

Study Status

In Development

IMPAACT 2028: Long-Term Clinical, Immunologic, and Virologic Profiles of Children who Received Early Treatment for HIV

DAIDS Number

38693

Research Area

Cure and Immunotherapy

Study Status

Enrolling